6:20 PM
 | 
Oct 23, 2012
 |  BC Extra  |  Company News

FDA rebuffs oral treprostinil

FDA issued a complete response letter for an NDA from United Therapeutics Corp. (NASDAQ:UTHR) for oral treprostinil to treat pulmonary arterial hypertension (PAH). According to the company, the agency questioned the clinical importance of the six-minute walk distance...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >